Advances in the Role of Angiogenesis Inhibitors and Their Application in Anti-tumor Therapy

In recent years, angiogenesis inhibitor drugs have been widely used in the course of anti-tumor therapy. An angiogenesis inhibitor can block the blood supply to the tumor tissue, resulting in hypoxia in the solid tumor tissue, which in turn causes tissue necrosis. Because there are significant differences in the process of angiogenesis between normal tissue and tumor tissue, this process provides new ways and ideas for the development of new anti-tumor drugs. As early as 1972, researchers had proposed methods for the treatment of solid tumors using angiogenesis inhibitors. At the beginning of the 21st century, FDA approved bevacizumab and sorafenib for the treatment of different types of neoplastic diseases. Over the past two decades, researchers had been improving the performance of angiogenesis inhibitor drugs and exploring possible mechanisms for their effective treatment of malignancies. This review mainly clarifies the different pathways of angiogenesis inhibitors, and discusses the clinical application of these drugs, which provide reference for the treatment of malignant tumors.